Retension Pharmaceuticals has priced its upsized initial public offering at $12 per share, aiming to raise $45 million before expenses. The company plans to use the proceeds to complete Phase 2b and advance Phase 3 clinical trials of its hypertension drug RTN-001. Trading is expected to begin on October 9, 2026, on Nasdaq under the ticker RTSN. This IPO supports Retension's focus on developing treatments for hypertension and cardiovascular diseases.
Retension Pharmaceuticals' IPO pricing is the subject, with Pluang's health sector data providing context. As of Oct 09, 2026 05:21 WIB, 51 of 128 health-sector US stocks rose while 77 fell on Pluang. Notable prices include RVMD at USD 187.99 with a 1-day change of -6.41%, IMVT at USD 30.01 down 6.34%, and ABCL at USD 12.09 down 5.77%.
Ipsen has disclosed its monthly update on the total number of shares and voting rights as of October 31, 2026. The company reported 83,814,526 shares composing the share capital, with a gross total of 132,059,377 voting rights and a net total of 130,...
Ipsen Pharma has disclosed the total number of shares and voting rights composing its capital as of October 31, 2026. The company reported 83,814,526 shares and a gross total of 132,059,377 voting rights, with a net total of 130,677,690 after excludi...
At its 2026 International User Summit, Chery unveiled its Globalization 3.0 strategy, moving beyond export-driven growth to emphasize deep localization, sustainable development, and community engagement. The company is expanding local R&D, manufactur...
Sodexo disclosed its monthly update on share capital and voting rights as of October 31, 2026. The company has 147,454,887 shares with actual voting rights totaling 216,485,145, reflecting shares with single and double voting rights. This update is p...
Sodexo announced its monthly update on the total number of shares and voting rights as of October 31, 2026. The company has 147,454,887 shares composing its capital, with 216,485,145 exercisable voting rights and 218,335,896 theoretical voting rights...
